Equities Analysts Offer Predictions for VRDN Q1 Earnings

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Research analysts at HC Wainwright decreased their Q1 2026 earnings per share (EPS) estimates for shares of Viridian Therapeutics in a research report issued on Monday, March 30th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($1.16) per share for the quarter, down from their prior forecast of ($1.11). HC Wainwright currently has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. HC Wainwright also issued estimates for Viridian Therapeutics’ Q2 2026 earnings at ($1.22) EPS, Q4 2026 earnings at ($1.17) EPS and FY2026 earnings at ($4.75) EPS.

A number of other research analysts also recently commented on VRDN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viridian Therapeutics in a research note on Wednesday, January 21st. Evercore reissued an “outperform” rating and issued a $44.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, January 20th. Royal Bank Of Canada lowered their target price on shares of Viridian Therapeutics from $45.00 to $42.00 and set an “outperform” rating for the company in a report on Friday, February 27th. The Goldman Sachs Group dropped their price target on shares of Viridian Therapeutics from $41.00 to $36.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Needham & Company LLC cut their price target on shares of Viridian Therapeutics from $42.00 to $32.00 and set a “buy” rating on the stock in a research note on Monday. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Viridian Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $39.21.

Viridian Therapeutics Stock Performance

NASDAQ VRDN opened at $19.56 on Wednesday. The business’s 50-day moving average price is $29.16 and its 200 day moving average price is $27.89. The company has a current ratio of 12.65, a quick ratio of 12.65 and a debt-to-equity ratio of 0.08. Viridian Therapeutics has a twelve month low of $9.90 and a twelve month high of $34.29. The company has a market capitalization of $2.00 billion, a PE ratio of -5.95 and a beta of 1.00.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.18). The business had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $15.75 million. Viridian Therapeutics had a negative net margin of 483.57% and a negative return on equity of 83.25%.

Hedge Funds Weigh In On Viridian Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of VRDN. Perceptive Advisors LLC raised its stake in shares of Viridian Therapeutics by 108.1% during the fourth quarter. Perceptive Advisors LLC now owns 3,042,703 shares of the company’s stock valued at $94,689,000 after purchasing an additional 1,580,303 shares during the period. Morgan Stanley boosted its stake in shares of Viridian Therapeutics by 805.6% in the fourth quarter. Morgan Stanley now owns 1,738,225 shares of the company’s stock valued at $54,094,000 after purchasing an additional 1,546,284 shares during the period. Avoro Capital Advisors LLC acquired a new stake in Viridian Therapeutics during the 4th quarter valued at $46,680,000. Vanguard Group Inc. grew its holdings in Viridian Therapeutics by 29.6% during the 4th quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock valued at $174,650,000 after purchasing an additional 1,280,161 shares in the last quarter. Finally, Commodore Capital LP increased its stake in Viridian Therapeutics by 35.4% during the 2nd quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock worth $68,152,000 after buying an additional 1,275,000 shares during the period.

More Viridian Therapeutics News

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: REVEAL‑1 hit its primary endpoint: elegrobart produced statistically significant proptosis responder rates (Q4W 54%, Q8W 63% vs placebo 18%) — an important clinical validation that supports a potential approval path. Business Wire release
• Positive Sentiment: Multiple outlets reported the positive topline data (press coverage that confirms the readout and its details may help downstream regulatory and partnering discussions). Las Vegas Sun article
• Positive Sentiment: Some sell‑side firms remain constructive despite cuts — Goldman Sachs cut its target to $36 but kept a “buy” rating, Wedbush cut to $37 and kept “outperform”, and Needham trimmed to $32 while retaining “buy” — these keep a material upside narrative for investors who focus on longer‑term commercial potential. Benzinga
• Neutral Sentiment: Market commentary and audio/newscasts are covering the swing (podcast coverage and “stocks to watch” lists) — reflects heightened attention but does not add new clinical or financial data. Bloomberg podcast
• Neutral Sentiment: News aggregators and analysts explain the paradox: the trial met its primary endpoint but market expectations for effect size, secondary endpoints, safety, dosing, or commercial assumptions may not have been met — this discussion is driving intraday volatility. Seeking Alpha
• Negative Sentiment: Several analysts trimmed price targets and/or lowered ratings: Wells Fargo cut target to $20 and moved to “equal weight”, HC Wainwright cut to $22 (still “buy”) — these downward revisions compress near‑term upside and signal more conservative commercial or launch assumptions. Benzinga
• Negative Sentiment: Despite positive topline data, the stock plunged (>30% in earlier trading) on investor disappointment and profit‑taking; coverage highlighting the selloff and “stock tumbles despite trial success” may amplify short‑term selling pressure. Investing.com

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.